NCT05331170招募中2 期
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma VIRAL MUCOSAL REPROGRAMMING
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- RV16 Viral Titer
研究概览
简要总结
This is a mechanistic, controlled, open-label, single-site study to evaluate the effects of RG-RV16 inoculation on airway mucosal gene expression and airway remodeling in 25 healthy controls (HC), in 25 allergic rhinitis subjects (AR) with cat dander allergy, and in 25 allergic asthmatic subjects (AA) with cat dander allergy. Three groups (HC, AR, and AA) will undergo screening to establish clinical history, will undergo pulmonary function testing (spirometry), and will have blood drawn for clinical characterization (IgE, , ImmunoCAP, CBC and differential), and for assessing the presence of existing neutralizing antibody against RV16. Only those who meet criteria will be permitted to continue into the interventional and run-out phases of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Normal Control Group
- •Subject must be able to understand and provide informed consent
- •Age: 18-60 inclusive
- •Sex: M or F
- •No history of asthma, COPD, rhinitis, or other clinically important respiratory disease
- •Non-smoker, or ex-smoker with <10 pack years, at least 5 years remote.
- •No history of diabetes or cardiovascular disease
- •Negative ImmunoCAP test to regionally relevant allergen panel obtained at Screening. Alternatively, documented history of a negative skin test or negative specific IgE obtained within the past 12 months.
- •Allergic Rhinitis Group
- •Subject must be able to understand and provide informed consent
- •Age: 18-60 inclusive
- •Sex: M or F
- •No history of asthma, COPD, or other clinically important respiratory disease
- •Non-smoker, or ex-smoker with <10 pack years, at least 5 years remote
- •No history of diabetes or cardiovascular disease
- •History of rhinitis, physician diagnosed, plus one of the following criteria within the past 12 months
- •Seasonal or perennial nasal congestion or sneezing
- •Seasonal or perennial conjunctival infection or watering
- •No evidence of airway obstruction (FEV1:FVC ≥ lower limit of normal)
- •Positive ImmunoCAP test to cat. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criterion. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.
- •Allergic Asthma Group
- •Inclusion Criteria
- •Subject must be able to understand and provide informed consent
- •Age: 18-60 inclusive
- •Sex: M or F
- •No history of COPD or other clinically important respiratory disease other than asthma
- •Non-smoker, or ex-smoker with <10 pack years, at least 5 years remote
- •No history of diabetes or cardiovascular disease
- •History of mild-moderate asthma, physician diagnosed, plus one of the following criteria within the past 12 months
- •Airway obstruction (FEV1: FVC <0.6) that is significantly (at least 12% change from baseline, ATS criteria) reversible after 4 puffs of albuterol (obtained at Screening Visit or documented historical testing performed with the past 12 months)
- •Requiring ICS for control of asthma for at least 30 days within the past 12 months
- •Positive ImmunoCAP test to cat dander. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criteria. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.
- •Results of the CBC do not show clinically important abnormalities
排除标准
- •Healthy Group Normal Group
- •Inability or unwillingness of a participant to comply with study protocol
- •Currently taking inhaled corticosteroids, leukotriene modifier, or antihistamines for respiratory disease.
- •Neutralizing Ab to RV16 greater than or equal to 1:8
- •Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at the screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
- •Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV).
- •Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
- •Allergic Rhinitis Group
- •Inability or unwillingness of a participant to comply with study protocol
- •Currently using inhaled steroids, or oral montelukast for respiratory disease
- •Neutralizing Ab to RV16 greater than or equal to 1:8
- •Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
- •Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .
- •Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
- •Subjects who have received immunosuppressive treatment within the last 12 months
- •BMI is greater than 35
- •History of symptoms consistent with a viral URI within the past 21 days
- •Results of the CBC do not show clinically important abnormalities
- •Family history or medical history of liver disease or bleeding disorders
- •Have not received systemic corticosteroids for 3months prior to Screening
- •Antiplatelet agents other than aspirin
- •Subjects who have a positive COVID-19 test will be excluded for 8 weeks
- •Allergic Asthma Group
- •Inability or unwillingness of a participant to comply with study protocol
- •Currently taking medications for respiratory diseases other than ICS, montelukast, or rescue albuterol or LABAs.
- •Neutralizing Ab to RV16 greater than or equal to 1:8
- •FEV1: FVC ratio less than 0.6, or FEV1 less than 60% predicted
- •Recent (<30 days) exacerbation of asthma requiring systemic corticosteroids
- •ICS greater than fluticasone 500 mcg/day or its equivalent (GINA 2019 table) at screening.
- •Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
- •Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .
- •Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
- •Subjects who have received immunosuppressive treatment within the last 12 months
- •BMI is greater than 35
- •History of symptoms consistent with a viral URI within the past 21 days
- •Family history or medical history of liver disease or bleeding disorders
- •Have not received systemic corticosteroids for 3 months prior to Screening
- •Have an ACT score >19 at the time of enrollment.
- •Antiplatelet agents other than aspirin
- •Subjects who have a positive COVID-19 test will be excluded for 8 weeks
研究组 & 干预措施
Healthy
Active Comparator
Subjects without asthma, COPD, rhinitis and with negative allergen test
干预措施: Research Grade RG-RV (Biological)
Allergic Rhinitis
Active Comparator
Subjects without asthma, COPD and with positive allergen test
干预措施: Research Grade RG-RV (Biological)
Allergic Ashthma
Active Comparator
Subjects with asthma and positive allergen test
干预措施: Research Grade RG-RV (Biological)
结局指标
主要结局
RV16 Viral Titer
时间窗: 48 hours after inoculation
Plaque Assays
Type III Interferon
时间窗: Immediate
Q-RT-PCR
PD-L1 Expression
时间窗: Immediate
Q-RT-PCR
ZEB-1 Expression
时间窗: Immediate
Q-PCR
次要结局
- URI Cold Symptoms(Immediate and up to 7 days following inoculation)
- Airway Remodeling(Immediate and 48 hrs post RV16 inoculation)
- CD8 T cells in bronchoalveolar lavage fluid(Immediate and 48hrs post RV16 inoculation)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The Role of Functional Epigenetic Modifications in Peri-ImplantitisPeriimplantitisNCT03753464NYU College of Dentistry15
已完成
1 期
A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and OlderHealthyNCT04354480Janssen Pharmaceutical K.K.36
已完成
3 期
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and AboveRespiratory Syncytial Virus InfectionsNCT05568797GlaxoSmithKline1,045
已完成
1 期
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy AdultsHuman Metapneumovirus and Human Parainfluenza InfectionNCT03392389ModernaTX, Inc.124
终止
2 期
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With FulvestrantBreast NeoplasmsNCT02374099Celgene97